Cardio Net Receivables from 2010 to 2026

CDIO Stock  USD 1.34  0.05  3.88%   
Cardio Diagnostics Net Receivables yearly trend continues to be very stable with very little volatility. Net Receivables is likely to grow to about 22.5 K this year. During the period from 2010 to 2026, Cardio Diagnostics Net Receivables quarterly data regression pattern had sample variance of 66.3 M and median of 0.00. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
21.4 K
Current Value
22.5 K
Quarterly Volatility
8.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Cardio Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardio Diagnostics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 333.7 K or Selling General Administrative of 9.9 M, as well as many indicators such as Price To Sales Ratio of 23.2 K, Dividend Yield of 0.0 or PTB Ratio of 84.57. Cardio financial statements analysis is a perfect complement when working with Cardio Diagnostics Valuation or Volatility modules.
  
Build AI portfolio with Cardio Stock
Check out the analysis of Cardio Diagnostics Correlation against competitors.
Evaluating Cardio Diagnostics's Net Receivables across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cardio Diagnostics Holdings's fundamental strength.

Latest Cardio Diagnostics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Cardio Diagnostics Holdings over the last few years. It is Cardio Diagnostics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardio Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Cardio Net Receivables Regression Statistics

Arithmetic Mean4,021
Geometric Mean0.00
Coefficient Of Variation202.46
Mean Deviation6,043
Median0.00
Standard Deviation8,140
Sample Variance66.3M
Range22.5K
R-Value0.71
Mean Square Error34.8M
R-Squared0.51
Significance0
Slope1,149
Total Sum of Squares1.1B

Cardio Net Receivables History

202622.5 K
202521.4 K
202418.6 K
2023 4960.0
2021 901.0

About Cardio Diagnostics Financial Statements

Cardio Diagnostics investors utilize fundamental indicators, such as Net Receivables, to predict how Cardio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables21.4 K22.5 K

Pair Trading with Cardio Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cardio Stock

  0.75DWTX Dogwood TherapeuticsPairCorr
  0.77EDIT Editas MedicinePairCorr

Moving against Cardio Stock

  0.57DSGN Design TherapeuticsPairCorr
  0.56ENGN enGene Holdings CommonPairCorr
  0.53IMMP Immutep Ltd ADRPairCorr
  0.4763E ONWARD MEDICAL BVPairCorr
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cardio Diagnostics is a strong investment it is important to analyze Cardio Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardio Diagnostics' future performance. For an informed investment choice regarding Cardio Stock, refer to the following important reports:
Check out the analysis of Cardio Diagnostics Correlation against competitors.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Biotechnology sector continue expanding? Could Cardio diversify its offerings? Factors like these will boost the valuation of Cardio Diagnostics. Projected growth potential of Cardio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cardio Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(11.91)
Revenue Per Share
0.01
Quarterly Revenue Growth
(0.57)
Return On Assets
(0.62)
Return On Equity
(1.11)
Cardio Diagnostics's market price often diverges from its book value, the accounting figure shown on Cardio's balance sheet. Smart investors calculate Cardio Diagnostics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cardio Diagnostics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cardio Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardio Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.